Compare VYGR & WALD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VYGR | WALD |
|---|---|---|
| Founded | 2013 | 1988 |
| Country | United States | United Kingdom |
| Employees | N/A | 364 |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 203.6M | 179.6M |
| IPO Year | 2015 | N/A |
| Metric | VYGR | WALD |
|---|---|---|
| Price | $3.48 | $1.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $16.50 | $2.00 |
| AVG Volume (30 Days) | 568.1K | ★ 605.0K |
| Earning Date | 05-08-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,135,000.00 | N/A |
| Revenue This Year | $34.04 | $9.89 |
| Revenue Next Year | $7.92 | $4.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.83 | $0.72 |
| 52 Week High | $5.55 | $3.22 |
| Indicator | VYGR | WALD |
|---|---|---|
| Relative Strength Index (RSI) | 43.51 | 64.24 |
| Support Level | $3.31 | $1.77 |
| Resistance Level | $4.29 | $2.03 |
| Average True Range (ATR) | 0.20 | 0.20 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 30.77 | 85.44 |
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.